Oncology
1 drug is in development for Castration-Resistant Prostatic Cancer.
- Companies
- 1
- Clinical trials
- 5
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Castration-Resistant Prostatic Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Lorigerlimab | MACROGENICS INC (MGNX) |
About this indication
Castration-Resistant Prostatic Cancer context
Oncology·MeSH: Prostatic Neoplasms, Castration-Resistant (D064129)
Narrower concept of MeSH descriptor Prostatic Neoplasms, Castration-Resistant
Frequently asked questions
How many drugs are in development for Castration-Resistant Prostatic Cancer?
BioSniper tracks 1 drug in development for Castration-Resistant Prostatic Cancer across 1 company.
How many clinical trials target Castration-Resistant Prostatic Cancer?
There are 5 clinical trials targeting Castration-Resistant Prostatic Cancer tracked by BioSniper.